Method for Diagnosing Prognosing Inflammatory Bowel Disease and Crohn's Disease

Abstract

Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 11 / 351,185, filed Feb. 8, 2006, which is a continuation-in-part of U.S. Ser. No. 10 / 843,033, filed May 11, 2004, which is a continuation-in-part of U.S. Ser. No. 10 / 728,227, filed Dec. 3, 2003. The contents of these applications are incorporated by reference in their entireties.FIELD OF THE INVENTION[0002]The invention relates generally to a method for diagnosing and / or predicting the prognosis of digestive diseases such as Inflammatory Bowel Disease (IBD), Crohn's disease (CD) and CD subtypes, as well as CD complications by detecting levels of antibodies to glycans in a subject.BACKGROUND OF THE INVENTION[0003]Inflammatory bowel disease (IBD), which occurs world-wide and afflicts millions of people, is the collective term used to describe several gastrointestinal disorders of unknown etiology: Crohn's disease (CD), ulcerative colitis (UC) and Indeterminate Colitis (IC). IBD, Celiac disease and irritable b...

AI Technical Summary

Benefits of technology

[0008]A further advantage of the invention is a panel of serological antibodies to certain sugar structures that provide these three different levels of information: first, whether or not a patient has IBD: second, if a patient does not have IBD, whether the patient has Crohn's disease; and third, for a patient that is diagnosed with Crohn's disease the severity and complications of the disease. This information can considerably shorten the period time for initiating appropriate treatment as well as reduce significantly the amount of time and number of procedures a patient will undergo until his diagnosis is accomplished. This facilitates earlier and more appropriate therapeutic intervention and minimizing uncertainty for patients and their families.

[0009]In one aspect, the invention provides a method of diagnosing IBD or Crohn's disease or predicting CD complications in a subject by providing a test sample from the subject and detecting in the test sample at least one of the following anti-glycan antibodies: an anti β-Glc antibody, an anti-Glc(β1,4)Glc(β) antibody, an anti-Glc(β1,3)Glc(β) antibody, an anti-Glc(β1,6)Glc(β) antibody, an anti-β-GlcNAc 6-sulfate antibody, an anti-Dextran antibody, an anti-Xylan antibody, an anti-GlcNAc(β1,4)GlcNAc(β) antibody, an anti-β-Gal 3-sulphate antibody, an anti-GlcNAc(β1,3)GalNAc(β) antibody, an anti-GlcNAc(β1,3)Gal(β1,4)Glc(β) antibody, an anti-α-Gal antibody, an anti-Gal(β) antibody, an anti-GalNAc(α) antibody, an anti-β-GalNAc antibody, an anti-α-Glc antibody, an anti-Gal(β1,6)Gal(β) antibody, an anti-Laminarin antibody, and an anti-GlcNAc(β1,6)GalNAc(α) antibody. The presence of one or more of the antibodies in the test sample indicates the subject has Crohn's disease.

[0010]In some embodiments, levels of the anti-glycan antibody or antibodies in the test sample are compared to the levels of anti-glycan antibodies in a control sample. The control sample is chosen from a group that includes one or more individuals known to have or not to have a gastrointestinal disorder, or to have or not to have a gastrointestinal disorder other than Crohn's disease. When the control sample is from an individual or individuals that do not have Crohn's disease, or has a gastrointestinal disease other than Crohn's disease, elevated levels in the test sample relative to the control sample indicates that the subject has Crohn's disease.

[0011]In some embodiments, the control sample is from one or more individuals with a gastrointestinal disorder that is irritable bowel syndrome, ulcerative colitis or other digestive diseases. In some embodiments, the control sample is from one or more individuals that do not have a gastrointestinal disorder.

[0012]In some embodiments, the control sample is from one or more individuals with a Crohn's disease with inflammation type of disease not suffering from fistulas or structuring disease.

[0013]In some embodiments, the control sample is from one or more individuals with a Crohn's disease that not underwent surgery.

Problems solved by technology

A primary determinant of these high medical costs is the difficulty of diagnosing digestive diseases.

The cost associated with IBD and IBS is compounded by lost productivity, with persons suffering from these disorders missing an average of at least eight more days of work annually than persons not suffering from these disorders.

This makes a definitive diagnosis of IBD, CD or UC extremely difficult.

The difficulty in differentially diagnosing IBD or CD from other digestive diseases like IBS hampers early and effective treatment of these diseases.

Images